(0.27%) 5 113.98 points
(0.30%) 38 353 points
(0.33%) 15 980 points
(-1.05%) $82.97
(5.36%) $2.03
(0.32%) $2 354.70
(0.41%) $27.65
(4.34%) $962.15
(-0.27%) $0.932
(-0.44%) $10.98
(-0.58%) $0.796
(1.68%) $93.42
0.97% $ 7.44
Live Chart Being Loaded With Signals
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments...
Stats | |
---|---|
Volumen de hoy | 235 563 |
Volumen promedio | 2.07M |
Capitalización de mercado | 29.24B |
EPS | $0 ( 2024-03-05 ) |
Próxima fecha de ganancias | ( $0 ) 2024-05-09 |
Last Dividend | $0.632 ( 2023-05-02 ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.30 |
ATR14 | $0.00600 (0.08%) |
Volumen Correlación
Bayer Aktiengesellschaft Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bayer Aktiengesellschaft Correlación - Moneda/Commodity
Bayer Aktiengesellschaft Finanzas
Annual | 2023 |
Ingresos: | $47.64B |
Beneficio Bruto: | $27.89B (58.54 %) |
EPS: | $-2.99 |
FY | 2023 |
Ingresos: | $47.64B |
Beneficio Bruto: | $27.89B (58.54 %) |
EPS: | $-2.99 |
FY | 2022 |
Ingresos: | $50.74B |
Beneficio Bruto: | $30.87B (60.84 %) |
EPS: | $4.22 |
Financial Reports:
No articles found.
Bayer Aktiengesellschaft Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.632 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.320 | 2001-04-25 |
Last Dividend | $0.632 | 2023-05-02 |
Next Dividend | $0 | N/A |
Payout Date | 2023-05-15 | |
Next Payout Date | N/A | |
# dividends | 24 | -- |
Total Paid Out | $12.19 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.58 | -- |
Div. Sustainability Score | 3.23 | |
Div.Growth Potential Score | 2.39 | |
Div. Directional Score | 2.81 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TYFG | Ex Dividend Junior | 2023-09-28 | Quarterly | 0 | 0.00% | |
JRONY | Ex Dividend Knight | 2023-05-15 | Annually | 0 | 0.00% | |
BPOSY | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
RMYHY | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
FCELB | Ex Dividend Junior | 2023-07-31 | Semi-Annually | 0 | 0.00% | |
VWAPY | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
LRENY | Ex Dividend Knight | 2023-06-30 | Quarterly | 0 | 0.00% | |
CKNQP | Ex Dividend Junior | 2023-09-14 | Quarterly | 0 | 0.00% | |
SKHHY | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
GTPS | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0617 | 1.500 | -1.235 | -1.852 | [0 - 0.5] |
returnOnAssetsTTM | -0.0238 | 1.200 | -0.795 | -0.954 | [0 - 0.3] |
returnOnEquityTTM | -0.0816 | 1.500 | -2.02 | -3.03 | [0.1 - 1] |
payoutRatioTTM | -0.809 | -1.000 | -8.09 | 8.09 | [0 - 1] |
currentRatioTTM | 1.259 | 0.800 | 8.70 | 6.96 | [1 - 3] |
quickRatioTTM | 0.784 | 0.800 | -0.0946 | -0.0757 | [0.8 - 2.5] |
cashRatioTTM | 0.201 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.355 | -1.500 | 4.08 | -6.11 | [0 - 0.6] |
interestCoverageTTM | 0.595 | 1.000 | -0.891 | -0.891 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.85 | 2.00 | 8.38 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.05 | 2.00 | 8.97 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.332 | -1.500 | 4.67 | -7.01 | [0 - 2.5] |
grossProfitMarginTTM | 0.585 | 1.000 | 3.58 | 3.58 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0333 | 1.000 | -1.333 | -1.333 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.109 | 1.000 | -0.507 | -0.507 | [0.2 - 2] |
assetTurnoverTTM | 0.386 | 0.800 | -0.759 | -0.607 | [0.5 - 2] |
Total Score | 3.23 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.30 | 1.000 | -0.333 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0816 | 2.50 | -1.297 | -3.03 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.05 | 2.00 | 9.32 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 9.49 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.85 | 2.00 | 8.38 | 10.00 | [0 - 30] |
payoutRatioTTM | -0.809 | 1.500 | -8.09 | 8.09 | [0 - 1] |
pegRatioTTM | 0.243 | 1.500 | -1.711 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.100 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 2.39 |
Bayer Aktiengesellschaft
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico